New heart tool aims to simplify AFib treatment

NCT ID NCT07428564

Recruiting now Disease control Sponsor: Biosense Webster, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study tests a new system (VARIPULSE catheter and TRUPULSE generator) with updated software for treating persistent atrial fibrillation, a long-lasting irregular heartbeat. About 50 adults aged 18-75 who have not responded to medication will undergo a heart ablation procedure. The main goal is to see how well the system works in practice, measuring procedure times and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

A.Z. Sint Jan
RECRUITING

Bruges, 8000, Belgium
AZORG campus Aalst Moorselbaan
RECRUITING

Aalst, 9300, Belgium
Aarhus University Hospital
RECRUITING

Aarhus N, 8200, Denmark
Azienda Ospedaliera Universitaria 'Policlinico Tor Vergata'
NOT_YET_RECRUITING

Roma, 00133, Italy
Erasmus MC
NOT_YET_RECRUITING

Rotterdam, 3015, Netherlands
Hospices Civils de Lyon HCL
NOT_YET_RECRUITING

Bron, 69500, France
IRCCS Policlinico San Donato
NOT_YET_RECRUITING

San Donato Milanese, 20097, Italy
Institut Medico chirurgical Montsouris
NOT_YET_RECRUITING

Paris, 75014, France
University Hospital of the Ruhr-University of Bochum
NOT_YET_RECRUITING

Bad Oeynhausen, 32545, Germany
Vilnius University Hospital Santaros Clinics
RECRUITING

Vilnius, 08406, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.